Showing 351-360 of 4174 results for "".
- Judge Blocks Launch of Xeomin for Aesthetic Indicationshttps://practicaldermatology.com/news/20120307-judge_blocks_launch_of_xeomin_for_aesthetic_indications/2459852/The planned March 12 launch of Merz's Xeomin (incobotulinumtoxinA) for aesthetic indications will almost certainly be delayed due to a court order blocking marketing of incobotulinumtoxinA. The order comes in response to a suit by
- Analysis: Estrogen Therapy Linked to Twofold Higher Odds of Porphyria Cutanea Tardahttps://practicaldermatology.com/news/analysis-estrogen-therapy-linked-to-twofold-higher-odds-of-porphyria-cutanea-tarda/2488877/New research published in JAMA Dermatology finds an association between estrogen-containing therapies and porphyria cutanea tarda, with differences observed by administration route. Researchers on the study examined whether estrogen exposure was associated with new PCT diagnoses a
- Analysis: Fewer Than Half of Patients With Multisite Mucous Membrane Pemphigoid Achieve Complete Remissionhttps://practicaldermatology.com/news/fewer-than-half-of-patients-with-multisite-mucous-membrane-pemphigoid-achieve-complete-remission/2488854/A retrospective study published in JAMA Dermatology indicated fewer than half of patients with multisite mucous membrane pemphigoid (MMP) achieved simultaneous complete remission across all affected sites, despite widespread improvement with treatment. Researchers at the
- VALOR Data Show Sustained Skin Improvement With Brepocitinibhttps://practicaldermatology.com/news/valor-data-show-sustained-skin-improvement-with-brepocitinib/2488826/Once-daily oral brepocitinib 30 mg demonstrated rapid and sustained improvements in cutaneous disease activity, pruritus, and skin-related quality of life among adults with dermatomyositis, according to a prespecified secondary analysis of the phase 3 VALOR trial published in JAMA Dermatology
- Study: Bimekizumab Achieves Complete Psoriasis Clearance in Most Patients at 2 Yearshttps://practicaldermatology.com/news/bimekizumab-achieves-complete-psoriasis-clearance-in-most-of-patients-at-2-years-study/2488814/A 2-year multicenter real-world study published in the Journal of the American Academy of Dermatology (JAAD) found that 71.1% of adults with plaque psoriasis treated with bimekizumab achieved complete skin clearance, with treatment persistence approaching 89% at week 104. The retrospective
- IL-23 Inhibitors Associated With Lowest Psoriatic Arthritis Incidence: Studyhttps://practicaldermatology.com/news/il-23-inhibitors-associated-with-lowest-psoriatic-arthritis-incidence-study/2488799/IL-23 Inhibitors Associated With Lowest Psoriatic Arthritis Incidence in Comparative Study Patients with psoriasis treated with interleukin (IL)-23 inhibitors had a lower observed incidence of psoriatic arthritis (PsA) than those receiving Janus kinase (JAK) inhibitors or IL-17 inhibitor
- Melanoma Risk Prediction Models Show Moderate Accuracy in Large Australian Cohorthttps://practicaldermatology.com/news/melanoma-risk-prediction-models-show-moderate-accuracy-in-large-australian-cohort/2488770/Six published melanoma risk prediction models demonstrated varying accuracy in identifying individuals who developed melanoma, with most underestimating absolute risk, according to a cohort study published in JAMA Dermatology. Melanoma Risk Prediction Accuracy and Study Findings<
- Study: Acupressure Improves Rosacea Severity, Reduces Inflammatory Biomarkershttps://practicaldermatology.com/news/study-acupressure-improves-rosacea-severity-reduces-inflammatory-biomarkers/2488756/Device-free auricular acupressure improved clinical outcomes and reduced inflammatory biomarkers in patients with rosacea receiving standard first-line treatment, according to findings from a trial published in JAMA Dermatology. The randomized, single-center, sham-controlled, asse
- Study Links Lichen Planus to Increased Oral and Genital Cancer Riskhttps://practicaldermatology.com/news/study-links-lichen-planus-to-increased-oral-and-genital-cancer-risk/2488704/A nationwide Danish cohort study found that patients with lichen planus (LP) had an increased risk of oral, genital, and cutaneous cancers, with the strongest associations observed at anatomical sites affected by the inflammatory condition. The findings, published in JAMA Dermatology, sh
- 2-Year ICONIC-LEAD Data Show Sustained Psoriasis Responses With Oral Icotrokinrahttps://practicaldermatology.com/news/2-year-iconic-lead-data-show-sustained-psoriasis-responses-with-oral-icotrokinra/2488701/Two-year findings from the Phase 3 ICONIC-LEAD trial showed sustained skin clearance and itch improvement with icotrokinra (ICOTYDE; Johnson & Johnson) in adults and adolescents aged 12 years or older with moderate-to-severe plaque psoriasis, according to data presented at the 2026 Fall Clini